American Journal of Physiology-Renal Physiology · 2018 · 29 citations · 38 references
MedicinePharmacologyPhysiologyDiabetologyRenal PathologyRenal PathophysiologyDiabetes MellitusDiabetes PharmacotherapyDiabetic NephropathyRenal DiseaseRenal PharmacologyRenal PhysiologyDiabetic GlomerulosclerosisDiabetic Kidney Disease ProgressionEndothelin Receptor AntagonistsEndothelin Receptor SignalingProteinuria ReductionRenal Fibrosis MechanismsRenin-angiotensin-aldosterone System Activation
The endothelin (ET) system has emerged as a therapeutic target for the treatment of diabetic nephropathy (DN). The present study examined whether chronic endothelin A (ET A ) receptor blockade with atrasentan prevents the progression of renal injury in two models of DN with preexisting renal disease that exhibit an increased renal ET-1 system compared with nondiabetic rats: streptozotocin-treated Dahl salt-sensitive (STZ-SS) and type 2 diabetic nephropathy (T2DN) rats. Nine week-old SS rats were treated with (STZ; 50 mg/kg ip) to induce diabetes. After 3 wk of diabetes, proteinuria increased to 353 ± 34 mg/day. The rats were then separated into two groups: 1) vehicle and 2) atrasentan (5 mg·kg −1 ·day −1 ) via drinking water. After 6 wk of treatment with atrasentan, mean arterial pressure (MAP) and proteinuria decreased by 12 and 40%, respectively, in STZ-SS rats. The degree of glomerulosclerosis and renal fibrosis was significantly reduced in the kidneys of atrasentan-treated STZ-SS rats compared with vehicle STZ-SS rats. Interestingly, treatment with atrasentan did not affect GFR but significantly increased renal blood flow by 33% and prevented the elevations in filtration fraction and renal vascular resistance by 23 and 20%, respectively, in STZ-SS rats. In contrast to the STZ-SS study, atrasentan had no effect on MAP or proteinuria in T2DN rats. However, treatment with atrasentan significantly decreased glomerular injury and renal fibrosis and prevented the decline in renal function in T2DN rats. These data indicate that chronic ET A blockade produces advantageous changes in renal hemodynamics that slow the progression of renal disease and also reduces renal histopathology in the absence of reducing arterial pressure and proteinuria.
38
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Masashi Yanagisawa, Hiroki Kurihara, Sadao Kimura et al. · Nature · 1988 · 10.8K citations · Full text
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Xiaoxin X. Wang, Jonathan Levi, Yuhuan Luo et al. · Journal of Biological Chemistry · 2017 · 302 citations · Full text
Jean-Claude Ansquer, Christelle Foucher, Stephanie Rattier et al. · American Journal of Kidney Diseases · 2005 · 266 citations